XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company that emerged from a SPAC business combination and was publicly reporting as of its 10-Q filing dated May 14, 2019, bearing SEC accession number 0001213900-19-008463. The company, identified in SEC records under CIK 0001697805, operates in the healthcare and life sciences sector with a focus on oncology drug development. The May 2019 quarterly filing reflects the company's status as an active reporting issuer following its de-SPAC transaction, placing it within the broader wave of pharmaceutical-focused blank-check mergers completed in that period. For the full filing history, sponsor details, deal structure, and current entity status, sign up for complete data access at SpacDesk.